We are comparing Adverum Biotechnologies Inc. (NASDAQ:ADVM) and Arvinas Holding Company LLC (NASDAQ:ARVN) on their institutional ownership, earnings and valuation, profitability, risk, dividends, analyst recommendations. They both are Biotechnology companies, competing one another.
Earnings & Valuation
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|Adverum Biotechnologies Inc.||2.00M||119.58||71.76M||-1.04||0.00|
|Arvinas Holding Company LLC||13.46M||57.20||233.06M||-7.47||0.00|
Demonstrates Adverum Biotechnologies Inc. and Arvinas Holding Company LLC earnings per share, top-line revenue and valuation.
Table 2 demonstrates the net margins, return on assets and return on equity of Adverum Biotechnologies Inc. and Arvinas Holding Company LLC.
|Net Margins||Return on Equity||Return on Assets|
|Adverum Biotechnologies Inc.||-3,588.00%||-32.7%||-30.8%|
|Arvinas Holding Company LLC||-1,731.50%||0%||0%|
The Current Ratio and Quick Ratio of Adverum Biotechnologies Inc. are 22.1 and 22.1 respectively. Its competitor Arvinas Holding Company LLC’s Current Ratio is 4.8 and its Quick Ratio is 4.8. Adverum Biotechnologies Inc. can pay off short and long-term obligations better than Arvinas Holding Company LLC.
Institutional & Insider Ownership
Adverum Biotechnologies Inc. and Arvinas Holding Company LLC has shares held by institutional investors as follows: 70.1% and 42.3%. About 1.2% of Adverum Biotechnologies Inc.’s share are held by insiders. Competitively, 13.1% are Arvinas Holding Company LLC’s share held by insiders.
Here are the Weekly, Monthly, Quarterly, Half Yearly, Yearly and YTD Performance of both pretenders.
|Performance (W)||Performance (M)||Performance (Q)||Performance (HY)||Performance (Y)||Performance (YTD)|
|Adverum Biotechnologies Inc.||2.51%||-0.27%||-45.07%||-40.65%||13.23%||5.14%|
|Arvinas Holding Company LLC||0.83%||-8.14%||0%||0%||0%||6.23%|
For the past year Adverum Biotechnologies Inc. was less bullish than Arvinas Holding Company LLC.
Arvinas Holding Company LLC beats on 6 of the 10 factors Adverum Biotechnologies Inc.
Adverum Biotechnologies, Inc., a gene therapy company, discovers and develops novel medicines for patients suffering from rare diseases or diseases of eye. The company has a pipeline that includes product candidates to treat wet age-related macular degeneration (wAMD), alpha 1 antitrypsin deficiency (A1AT), and hereditary angioedema. Its lead gene therapy programs include ADVM-022 and ADVM-032, which are in the preclinical development of new anti-VEGF gene therapy candidates for wAMD diseases; and ADVM-043, which is in patient enrollment in a phase 1/2 trial for the treatment of A1AT. The company is also developing ADVM-053 to treat hereditary angioedema; and other product candidates, such as ocular therapeutics, including AVA-311 for the treatment of juvenile X-linked retinoschisis. It has collaboration agreements with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize gene therapy products for ophthalmic diseases; and Editas Medicine, Inc. to explore the delivery of genome editing medicines for the treatment of inherited retinal diseases. The company was formerly known as Avalanche Biotechnologies, Inc. and changed its name to Adverum Biotechnologies, Inc. in May 2016. Adverum Biotechnologies, Inc. was founded in 2006 and is headquartered in Menlo Park, California.
Arvinas Holding Company, LLC, a biopharmaceutical company, engages in the discovery, development, and commercialization of therapies to degrade disease-causing proteins. Its lead products include ARV-110, proteolysis targeting chimeras (PROTAC) targeting the androgen receptor (AR) protein for the treatment of men with metastatic castration-resistant prostate cancer; and ARV-471, a PROTAC targeting the estrogen receptor protein for the treatment of women with metastatic ER+ breast cancer. The company is also developing other PROTACs for degrading AR and other clinically relevant AR point mutations; and various other products for the treatment of neurodegenerative diseases, including tauopathies. Arvinas Holding Company, LLC was founded in 2015 and is based in New Haven, Connecticut.